Stimulants and ADHD medications and psilocybin.
23 records in this group. 1 has published human data with psilocybin or another classic psychedelic; the rest draw on each medication's own pharmacology and label. State rules are summarized for Colorado, Oregon and New Mexico.
Overview
Reviewed 2026-10-14Stimulant and ADHD medications have almost no published human data with psilocybin. Amphetamines and methylphenidate are sympathomimetic (adrenaline-like) and raise blood pressure and heart rate (amphetamine and methylphenidate prescribing information). Psilocybin has been shown to raise heart rate and blood pressure in some healthy adults (Becker 2022), so the two effects may add together.
One case report describes a hypertensive emergency, with chest pain, palpitations and headache, after psilocybin mushrooms were taken with tranylcypromine (an MAO inhibitor) and extended-release dextroamphetamine-amphetamine (Adderall XR). The authors attributed it to phenylethylamine in the mushrooms interacting with both drugs (Barnett 2024). Amphetamine prescribing information lists MAO inhibitors as a contraindication because of the risk of hypertensive crisis, with or without psilocybin.
Non-stimulant ADHD medications work differently. Atomoxetine and viloxazine block noradrenaline reuptake and can also raise heart rate and blood pressure. Clonidine and guanfacine lower blood pressure, and stopping them suddenly can cause rebound high blood pressure (atomoxetine, viloxazine, clonidine and guanfacine prescribing information). Each record lists the facts from that medication's own label.
Psilodex presents published evidence and state psilocybin regulations for information only. It is not medical advice, a screening decision, or clearance to participate. Do not stop or change a medication without talking with the prescriber.
- Becker AM, Holze F, Grandinetti T, et al. Acute effects of psilocybin after escitalopram or placebo pretreatment. Clin Pharmacol Ther 2022;111(4):886–895.
- Barnett BS, Koons CJ, Van den Eynde V, et al. Hypertensive emergency secondary to combining psilocybin mushrooms, extended release dextroamphetamine-amphetamine, and tranylcypromine. J Psychoactive Drugs 2024;57(3):297–303.
- Dextroamphetamine–amphetamine extended-release (Adderall XR generic) prescribing information (DailyMed)
- Concerta (methylphenidate) prescribing information (DailyMed)
- Strattera (atomoxetine) prescribing information (DailyMed)
- Qelbree (viloxazine) prescribing information (DailyMed)
- Catapres-TTS (clonidine) prescribing information (DailyMed)
- Intuniv (guanfacine) prescribing information (DailyMed)
Also searched as stimulant · stimulants · ADHD medication · ADHD meds · ADHD
01 What the evidence covers
Best evidence available per medication| 1 | Case reports Case reports or online surveys |
| 22 | No psilocybin data No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts |
02 Each medication
A to Z- 4-FA (4-fluoroamphetamine)Evidence: No psilocybin data
Other substances
Not studied with psilocybin; this stimulant strongly raises blood pressure and heart rate, so adding to psilocybin's own rises is possible.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- Amphetamine (including mixed amphetamine salts) · Adderall, Adderall XR, MydayisEvidence: Case reports
ADHD (attention-deficit/hyperactivity disorder); Narcolepsy (immediate-release tablets)
It may add to psilocybin's blood pressure, heart rate and anxiety rises; one case also involving the MAOI tranylcypromine had a hypertensive emergency.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Excessive sleepiness from obstructive sleep apnea (OSA), narcolepsy, or shift work disorder
It may add to psilocybin's blood pressure, heart rate and anxiety effects. Its liver-enzyme effect skips the main routes that clear psilocybin.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
ADHD (attention-deficit/hyperactivity disorder)
It may add to psilocybin's blood pressure and heart rate rise. Also, it can cause psychotic or manic symptoms, even without that history.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- Caffeine, guarana, pre-workoutEvidence: No psilocybin data
Temporary fatigue or drowsiness (restoring alertness)
Its caffeine raises blood pressure, heart rate and anxiety, which may add to psilocybin's rise. Stopping it suddenly after regular use can cause withdrawal.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
ADHD (attention-deficit/hyperactivity disorder) in adults and children 6 years and older
As a stimulant, it may add to psilocybin's rise in blood pressure, heart rate and anxiety. Its label also warns of serotonin syndrome.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
High blood pressure; ADHD (attention-deficit/hyperactivity disorder; extended-release)
It may blunt psilocybin's blood pressure rise but has no known direct interaction. Stopping it suddenly after regular use can cause rebound high blood pressure.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- CocaineEvidence: No psilocybin data
Other substances
Its rise in blood pressure and heart rate may add to psilocybin's. Also, it can cause heart rhythm problems, seizures and paranoia.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Attention-deficit/hyperactivity disorder (ADHD)
As a stimulant, it may add to psilocybin's rise in blood pressure, heart rate and anxiety.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Narcolepsy; ADHD (attention-deficit/hyperactivity disorder)
As a stimulant, it may add to psilocybin's rise in blood pressure, heart rate and anxiety. Also, it can cause psychotic or manic symptoms.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- DMAA / DMHA stimulantsEvidence: No psilocybin data
Supplements and over the counter
Its blood pressure and heart rate rise may add to psilocybin's. Also, it is linked to heart rhythm problems, heart attack and seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Attention-deficit/hyperactivity disorder (ADHD) (extended-release); High blood pressure (immediate-release)
It may dampen psilocybin's blood pressure rise and can cause dizziness on standing. Stopping it suddenly after regular use can cause rebound high blood pressure.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- KhatEvidence: No psilocybin data
Other substances
Not studied with psilocybin; chewing it raises blood pressure and heart rate, as psilocybin does; heavy use is linked to psychosis-like symptoms and heart attacks.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Attention-deficit/hyperactivity disorder (ADHD); Binge eating disorder (moderate to severe, adults)
It may add to psilocybin's rise in blood pressure, heart rate and anxiety. Also, it can worsen psychotic symptoms.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Attention-deficit/hyperactivity disorder (ADHD)
It may add to psilocybin's rise in blood pressure, heart rate and anxiety. Also, it can cause psychotic or manic symptoms.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Attention-deficit/hyperactivity disorder (ADHD); Narcolepsy (immediate-release Ritalin)
As a stimulant, it may add to psilocybin's rise in blood pressure, heart rate and anxiety.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Excessive sleepiness from narcolepsy; Excessive sleepiness from obstructive sleep apnea
Its stimulant-like effects on blood pressure, heart rate and anxiety may add to psilocybin's.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Obesity (short-term, with diet, exercise and behavior change)
Not studied with psilocybin; it raises blood pressure and heart rate, so an added rise is possible.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Weight management in obesity (adults and ages 12+) or adult overweight with a weight-related condition (with diet and exercise)
Phentermine's rise in blood pressure and heart rate may add to psilocybin's. Stopping it suddenly after regular use can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Attention-deficit/hyperactivity disorder (ADHD)
As a stimulant, it may add to psilocybin's rise in blood pressure, heart rate and anxiety.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Excessive daytime sleepiness in narcolepsy; Excessive daytime sleepiness in obstructive sleep apnea (OSA)
It may add to psilocybin's rise in blood pressure, heart rate and anxiety. Also, its label describes possible psychiatric symptoms.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- Synthetic cathinones ("bath salts")Evidence: No psilocybin data
Other substances
Not studied with psilocybin; these amphetamine-like stimulants are linked to fast heartbeat, high blood pressure, overheating, seizures, psychosis and serotonin syndrome.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Attention-deficit/hyperactivity disorder (ADHD)
It raises blood pressure and heart rate, which may add to psilocybin's rise. Also, its label warns of suicidal thoughts, mania and sleepiness.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
03 Properties the records flag
Records with each flag| 21 | Raises blood pressure or heart rate |
| 17 | Psychiatric reactions |
| 10 | Withdrawal or rebound if stopped abruptly |
| 8 | Serotonergic |
| 7 | Lowers seizure threshold or carries seizure risk |
| 4 | Sedating or CNS depressant |
| 3 | Lowers blood pressure or causes orthostasis |
| 3 | Speeds up drug metabolism |
| 2 | Liver injury |
| 1 | QT-prolonging |
Flags describe a medication's own properties, each cited in its record. A flag is not a finding about any combination. Definitions are on the Method page.
04 State rules
Official text governsNo provision names these medications or this group.
Rule 2.2(A)(9): a facilitator must tell prospective participants in writing that anyone taking a psychotropic medication identified as a risk factor on the safety screen must meet one of the 2.2(A)(7) conditions. 16 of the 23 medications in this group are psychotropic; the rule applies when one is identified as a risk factor on a participant's screen.
No provision names these medications or this group.
Rules not final; the proposed rules reviewed name no medication in this group.
05 Studies cited in this group
Records citing eachRelated classes
Records reviewed 2026-10-03 to 2026-11-02. Each row summarizes one record; the full record, with every source, opens in the browser and is not sent to the server. All classes · Browse A–Z